U.S. Markets open in 44 mins

Equillium, Inc. (EQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.72+0.30 (+5.54%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.42
Open5.34
Bid5.65 x 3200
Ask6.20 x 1100
Day's Range5.34 - 5.75
52 Week Range2.37 - 27.05
Volume43,300
Avg. Volume476,870
Market Cap166.111M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study

    Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the study showed that itolizumab was safe and well-tolerated and demonstrated a dose-dependent reduction of cell-surface CD6 expression on effector T cells, a leading indicator of drug activity. The most frequent adverse events were mild to moderate injection site reactions. In the Type A SLE group, a total of 34 patients received at least one dose of subcutaneously delivered itolizumab in dosing cohorts 0.4 mg/kg through 2.4 mg/kg. For the highest dosing cohort (3.2 mg/kg), a total of eight subjects received at least one subcutaneous dose of itolizumab. Of those, four patients discontinued in the highest dosing cohort after one dose, two due to non-serious adverse events, and two due to voluntary patient discontinuation. Changes in pharmacodynamic markers were consistent with the pharmacokinetics and mechanism of action of itolizumab. The company says that in terms of potency, the pharmacodynamic data from the cohort receiving 1.6 mg/kg subcutaneously in the EQUALISE study is comparable to the 1.6 mg/kg cohort in the intravenously administered EQUATE study in patients with acute graft-versus-host disease. Complete data set from the Type A SLE patients will be presented at a future medical conference. Interim data from the Type B Lupus Nephritis patients are expected to be announced before the end of the year. Itolizumab is an anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive many immuno-inflammatory diseases. Price Action: EQ shares are trading 5.9% higher at $7 in the premarket on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaKamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 TrialPfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Equillium Reports Positive Itolizumab Phase 1 Data; Shares Rise 7.6% After-Hours
    SmarterAnalyst

    Equillium Reports Positive Itolizumab Phase 1 Data; Shares Rise 7.6% After-Hours

    Clinical stage biotechnology company Equillium Inc. reported positive data from its Phase 1 EQUALISE study evaluating Itolizumab in patients with systemic lupus erythematosus (SLE). Shares rose about 7.6% in Tuesday’s extended trading session. Equillium’s (EQ) Itolizumab, a monoclonal antibody, was designed for the treatment of severe autoimmune and inflammatory disorders. In the study, the drug was found to be safe and well tolerated. Equillium’s Chief Medical Officer, Dolca Thomas, M.D., said, “These initial data from the EQUALISE study demonstrate a favourable safety and tolerability profile for subcutaneous delivery of itolizumab in SLE patients, with the most frequent adverse events being mild to moderate injection site reactions.” Thomas further added, “We look forward to assessing outcomes with six months of subcutaneous itolizumab administration in the Type B EQUALISE study in lupus nephritis patients.” The company expects to present complete data from Type A SLE patients at a future medical conference. It plans to announce interim data from Type B LN patients before the end of 2021. (See Equillium stock analysis on TipRanks) On March 25, Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on the stock and lowered the price target to $13 (96.7% upside potential) from $14. Archila commented, “We believe there are several clinical catalysts that will de-risk itolizumab in multiple indications this year. At its current valuation, we think the stock reflects mostly risk-adjusted value in aGVHD leaving opportunities in systemic lupus/lupus nephritis and asthma as free call options.” Turning to the rest of the Street, the stock has a Strong Buy consensus rating alongside an average analyst price target of $15.60 (136% upside potential), based on 5 unanimous Buys. Shares have gained about 154.2% over the past year. Related News: Canoo’s 4Q Loss Improves On Electric Vehicles Strength McCormick’s 1Q Results Beat Expectations As Sales Outperform Digi International Rises On Haxiot Acquisition; Street Remains Bullish More recent articles from Smarter Analyst: Amgen Snaps Up Rodeo Therapeutics For $721M Academy’s 4Q Results Beat Estimates; Shares Jump 11% Lululemon’s FY21 Outlook Surpasses Estimates After 4Q Beat Wednesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens

  • Benzinga

    Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021

    Upgrades According to Wolfe Research, the prior rating for Fisker Inc (NYSE:FSR) was changed from Underperform to Peer Perform. In the fourth quarter, Fisker earned $0.05. At the moment, the stock has a 52-week-high of $31.96 and a 52-week-low of $14.32. Fisker closed at $28.16 at the end of the last trading period. According to Piper Sandler, the prior rating for Farmers National Banc Corp (NASDAQ:FMNB) was changed from Neutral to Overweight. Farmers National Banc earned $0.45 in the fourth quarter, compared to $0.35 in the year-ago quarter. The stock has a 52-week-high of $15.43 and a 52-week-low of $9.82. At the end of the last trading period, Farmers National Banc closed at $14.29. For Itron Inc (NASDAQ:ITRI), Argus Research upgraded the previous rating of Hold to Buy. For the fourth quarter, Itron had an EPS of $0.65, compared to year-ago quarter EPS of $0.72. The stock has a 52-week-high of $120.80 and a 52-week-low of $40.48. At the end of the last trading period, Itron closed at $117.75. According to Baird, the prior rating for WillScot Mobile Mini Holdings Corp (NASDAQ:WSC) was changed from Neutral to Outperform. The current stock performance of WillScot Mobile Mini shows a 52-week-high of $28.71 and a 52-week-low of $7.45. Moreover, at the end of the last trading period, the closing price was at $27.20. According to Raymond James, the prior rating for Iridium Communications Inc (NASDAQ:IRDM) was changed from Market Perform to Outperform. For the fourth quarter, Iridium Communications had an EPS of $0.06, compared to year-ago quarter EPS of $0.82. The stock has a 52-week-high of $54.65 and a 52-week-low of $16.87. At the end of the last trading period, Iridium Communications closed at $39.47. According to Loop Capital, the prior rating for 3D Systems Corp (NYSE:DDD) was changed from Sell to Hold. In the fourth quarter, 3D Sys showed an EPS of $0.09, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $56.50 and a 52-week-low of $4.60. At the end of the last trading period, 3D Sys closed at $31.14. For Eaton Corp PLC (NYSE:ETN), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. In the fourth quarter, Eaton Corp showed an EPS of $1.28, compared to $1.37 from the year-ago quarter. The current stock performance of Eaton Corp shows a 52-week-high of $135.84 and a 52-week-low of $56.41. Moreover, at the end of the last trading period, the closing price was at $133.92. Goldman Sachs upgraded the previous rating for Alcoa Corp (NYSE:AA) from Sell to Buy. For the fourth quarter, Alcoa had an EPS of $0.26, compared to year-ago quarter EPS of $0.31. The current stock performance of Alcoa shows a 52-week-high of $27.86 and a 52-week-low of $5.16. Moreover, at the end of the last trading period, the closing price was at $27.50. For Rapid7 Inc (NASDAQ:RPD), Piper Sandler upgraded the previous rating of Neutral to Overweight. For the fourth quarter, Rapid7 had an EPS of $0.07, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $94.60 and a 52-week-low of $31.34. Rapid7 closed at $78.99 at the end of the last trading period. According to JP Morgan, the prior rating for Casa Systems Inc (NASDAQ:CASA) was changed from Underweight to Neutral. Casa Systems earned $0.27 in the fourth quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.15 and a 52-week-low of $1.85. Casa Systems closed at $8.02 at the end of the last trading period. JP Morgan upgraded the previous rating for Sensata Technologies Holding PLC (NYSE:ST) from Neutral to Overweight. For the fourth quarter, Sensata Technologies had an EPS of $0.85, compared to year-ago quarter EPS of $0.89. The current stock performance of Sensata Technologies shows a 52-week-high of $61.64 and a 52-week-low of $18.25. Moreover, at the end of the last trading period, the closing price was at $59.68. According to KeyBanc, the prior rating for Roku Inc (NASDAQ:ROKU) was changed from Sector Weight to Overweight. Roku earned $0.49 in the fourth quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $486.72 and a 52-week-low of $58.22. Roku closed at $389.67 at the end of the last trading period. See all analyst ratings upgrades. Downgrades For Camden Property Trust (NYSE:CPT), ScotiaBank downgraded the previous rating of Outperform to Sector Perform. In the fourth quarter, Camden Prop Trust showed an EPS of $1.00, compared to $1.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $115.03 and a 52-week-low of $62.48. Camden Prop Trust closed at $103.69 at the end of the last trading period. According to HC Wainwright & Co., the prior rating for Kopin Corp (NASDAQ:KOPN) was changed from Buy to Neutral. For the fourth quarter, Kopin had an EPS of $0.02, compared to year-ago quarter EPS of $0.09. The current stock performance of Kopin shows a 52-week-high of $13.62 and a 52-week-low of $0.19. Moreover, at the end of the last trading period, the closing price was at $9.91. For Adaptive Biotechnologies Corp (NASDAQ:ADPT), Goldman Sachs downgraded the previous rating of Buy to Neutral. For the fourth quarter, Adaptive Biotechnologies had an EPS of $0.33, compared to year-ago quarter EPS of $0.17. The current stock performance of Adaptive Biotechnologies shows a 52-week-high of $71.25 and a 52-week-low of $15.19. Moreover, at the end of the last trading period, the closing price was at $53.11. Mizuho downgraded the previous rating for Black Hills Corp (NYSE:BKH) from Buy to Neutral. In the fourth quarter, Black Hills showed an EPS of $1.23, compared to $1.13 from the year-ago quarter. The current stock performance of Black Hills shows a 52-week-high of $81.43 and a 52-week-low of $48.07. Moreover, at the end of the last trading period, the closing price was at $59.94. According to Goldman Sachs, the prior rating for Owens-Corning Inc (NYSE:OC) was changed from Buy to Sell. Owens-Corning earned $1.90 in the fourth quarter, compared to $1.13 in the year-ago quarter. The current stock performance of Owens-Corning shows a 52-week-high of $87.89 and a 52-week-low of $28.56. Moreover, at the end of the last trading period, the closing price was at $83.09. According to RBC Capital, the prior rating for Rocket Companies Inc (NYSE:RKT) was changed from Outperform to Sector Perform. Rocket Companies earned $1.14 in the fourth quarter. The current stock performance of Rocket Companies shows a 52-week-high of $43.00 and a 52-week-low of $17.78. Moreover, at the end of the last trading period, the closing price was at $41.60. According to Piper Sandler, the prior rating for KeyCorp (NYSE:KEY) was changed from Overweight to Neutral. In the fourth quarter, KeyCorp showed an EPS of $0.56, compared to $0.48 from the year-ago quarter. The stock has a 52-week-high of $21.81 and a 52-week-low of $7.45. At the end of the last trading period, KeyCorp closed at $20.64. Berenberg downgraded the previous rating for LivaNova PLC (NASDAQ:LIVN) from Buy to Hold. For the fourth quarter, LivaNova had an EPS of $0.71, compared to year-ago quarter EPS of $1.00. The current stock performance of LivaNova shows a 52-week-high of $79.98 and a 52-week-low of $33.40. Moreover, at the end of the last trading period, the closing price was at $76.23. For Prudential Financial Inc (NYSE:PRU), JP Morgan downgraded the previous rating of Overweight to Neutral. Prudential Financial earned $2.93 in the fourth quarter, compared to $2.33 in the year-ago quarter. The current stock performance of Prudential Financial shows a 52-week-high of $91.61 and a 52-week-low of $38.62. Moreover, at the end of the last trading period, the closing price was at $88.94. See all analyst ratings downgrades. Initiations JonesTrading initiated coverage on Equillium Inc (NASDAQ:EQ) with a Buy rating. The price target for Equillium is set to $14.00. For the third quarter, Equillium had an EPS of $0.31, compared to year-ago quarter EPS of $0.35. The current stock performance of Equillium shows a 52-week-high of $27.05 and a 52-week-low of $2.20. Moreover, at the end of the last trading period, the closing price was at $7.20. With a Buy rating, Jefferies initiated coverage on Gemini Therapeutics Inc (NASDAQ:GMTX). The price target seems to have been set at $23.00 for Gemini Therapeutics. The stock has a 52-week-high of $16.64 and a 52-week-low of $11.06. At the end of the last trading period, Gemini Therapeutics closed at $16.01. With an Outperform rating, Bernstein initiated coverage on NextEra Energy Inc (NYSE:NEE). The price target seems to have been set at $88.00 for NextEra Energy. In the fourth quarter, NextEra Energy showed an EPS of $0.40, compared to $1.44 from the year-ago quarter. The stock has a 52-week-high of $1232.24 and a 52-week-low of $71.94. At the end of the last trading period, NextEra Energy closed at $75.56. For Resideo Technologies Inc (NYSE:REZI), William Blair initiated coverage, by setting the current rating at Market Perform. In the fourth quarter, Resideo Technologies showed an EPS of $0.44, compared to $0.39 from the year-ago quarter. The stock has a 52-week-high of $29.48 and a 52-week-low of $3.72. At the end of the last trading period, Resideo Technologies closed at $25.81. With an Outperform rating, Evercore ISI Group initiated coverage on Vor Biopharma Inc (NASDAQ:VOR). The price target seems to have been set at $48.00 for Vor Biopharma. The current stock performance of Vor Biopharma shows a 52-week-high of $63.62 and a 52-week-low of $25.32. Moreover, at the end of the last trading period, the closing price was at $42.59. Barclays initiated coverage on Danaher Corp (NYSE:DHR) with an Overweight rating. The price target for Danaher is set to $260.00. Danaher earned $2.08 in the fourth quarter, compared to $1.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $248.86 and a 52-week-low of $119.60. Danaher closed at $223.93 at the end of the last trading period. Oppenheimer initiated coverage on ChargePoint Holdings Inc (NYSE:CHPT) with an Outperform rating. The price target for ChargePoint Holdings is set to $39.00. The current stock performance of ChargePoint Holdings shows a 52-week-high of $33.35 and a 52-week-low of $28.00. Moreover, at the end of the last trading period, the closing price was at $28.57. Barclays initiated coverage on Thermo Fisher Scientific Inc (NYSE:TMO) with an Overweight rating. The price target for Thermo Fisher Scientific is set to $525.00. In the fourth quarter, Thermo Fisher Scientific showed an EPS of $7.09, compared to $3.55 from the year-ago quarter. The current stock performance of Thermo Fisher Scientific shows a 52-week-high of $532.57 and a 52-week-low of $250.21. Moreover, at the end of the last trading period, the closing price was at $463.20. With a Equal-Weight rating, Barclays initiated coverage on Syneos Health Inc (NASDAQ:SYNH). The price target seems to have been set at $84.00 for Syneos Health. In the fourth quarter, Syneos Health showed an EPS of $1.11, compared to $1.03 from the year-ago quarter. The current stock performance of Syneos Health shows a 52-week-high of $81.35 and a 52-week-low of $30.02. Moreover, at the end of the last trading period, the closing price was at $75.50. Barclays initiated coverage on PPD Inc (NASDAQ:PPD) with an Overweight rating. The price target for PPD is set to $42.00. For the fourth quarter, PPD had an EPS of $0.39, compared to year-ago quarter EPS of $0.33. The current stock performance of PPD shows a 52-week-high of $38.76 and a 52-week-low of $10.61. Moreover, at the end of the last trading period, the closing price was at $35.99. With an Overweight rating, Barclays initiated coverage on Sotera Health Co (NASDAQ:SHC). The price target seems to have been set at $35.00 for Sotera Health. The current stock performance of Sotera Health shows a 52-week-high of $28.62 and a 52-week-low of $24.36. Moreover, at the end of the last trading period, the closing price was at $26.56. Barclays initiated coverage on Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) with an Overweight rating. The price target for Ortho Clinical Diagnostic is set to $24.00. At the moment, the stock has a 52-week-high of $18.65 and a 52-week-low of $15.14. Ortho Clinical Diagnostic closed at $17.57 at the end of the last trading period. Barclays initiated coverage on IQVIA Holdings Inc (NYSE:IQV) with an Overweight rating. The price target for IQVIA Holdings is set to $220.00. IQVIA Holdings earned $2.11 in the fourth quarter, compared to $1.74 in the year-ago quarter. The stock has a 52-week-high of $199.99 and a 52-week-low of $81.79. At the end of the last trading period, IQVIA Holdings closed at $192.65. With a Equal-Weight rating, Barclays initiated coverage on Icon PLC (NASDAQ:ICLR). The price target seems to have been set at $200.00 for Icon. Icon earned $1.90 in the fourth quarter, compared to $1.83 in the year-ago quarter. The current stock performance of Icon shows a 52-week-high of $223.62 and a 52-week-low of $104.28. Moreover, at the end of the last trading period, the closing price was at $171.87. With an Overweight rating, Barclays initiated coverage on Certara Inc (NASDAQ:CERT). The price target seems to have been set at $40.00 for Certara. The current stock performance of Certara shows a 52-week-high of $41.79 and a 52-week-low of $29.70. Moreover, at the end of the last trading period, the closing price was at $35.49. Needham initiated coverage on CuriosityStream Inc (NASDAQ:CURI) with a Buy rating. The price target for CuriosityStream is set to $25.00. Interestingly, in the third quarter, CuriosityStream's EPS was $0.56. The current stock performance of CuriosityStream shows a 52-week-high of $24.00 and a 52-week-low of $7.44. Moreover, at the end of the last trading period, the closing price was at $18.63. With an Overweight rating, Barclays initiated coverage on Avantor Inc (NYSE:AVTR). The price target seems to have been set at $33.00 for Avantor. In the fourth quarter, Avantor showed an EPS of $0.29, compared to $0.19 from the year-ago quarter. The stock has a 52-week-high of $31.05 and a 52-week-low of $6.66. At the end of the last trading period, Avantor closed at $28.74. Barclays initiated coverage on Illumina Inc (NASDAQ:ILMN) with an Underweight rating. The price target for Illumina is set to $325.00. In the fourth quarter, Illumina showed an EPS of $1.22, compared to $1.70 from the year-ago quarter. The current stock performance of Illumina shows a 52-week-high of $555.77 and a 52-week-low of $196.78. Moreover, at the end of the last trading period, the closing price was at $441.01. KeyBanc initiated coverage on OneWater Marine Inc (NASDAQ:ONEW) with an Overweight rating. The price target for OneWater Marine is set to $43.00. Interestingly, in the first quarter, OneWater Marine's EPS was $0.71. The stock has a 52-week-high of $38.71 and a 52-week-low of $3.41. At the end of the last trading period, OneWater Marine closed at $37.24. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaA Look Into AutoZone's Price Over EarningsP/E Ratio Insights for B&G Foods© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.